Polar Capital Holdings Plc Buys New Shares in Savara Inc. $SVRA

Polar Capital Holdings Plc bought a new stake in shares of Savara Inc. (NASDAQ:SVRA) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 8,306,196 shares of the company’s stock, valued at approximately $50,086,000. Polar Capital Holdings Plc owned 4.08% of Savara as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Swedbank AB lifted its position in shares of Savara by 54.5% during the 4th quarter. Swedbank AB now owns 850,000 shares of the company’s stock valued at $5,126,000 after acquiring an additional 300,000 shares during the period. F m Investments LLC raised its holdings in Savara by 56.5% during the fourth quarter. F m Investments LLC now owns 678,813 shares of the company’s stock worth $4,093,000 after buying an additional 245,100 shares during the last quarter. Nan Fung Trinity HK Ltd. acquired a new position in Savara during the fourth quarter worth $10,182,000. Rosalind Advisors Inc. raised its holdings in Savara by 50.7% during the third quarter. Rosalind Advisors Inc. now owns 4,000,000 shares of the company’s stock worth $14,280,000 after buying an additional 1,345,056 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in Savara by 20.8% during the fourth quarter. Vanguard Group Inc. now owns 10,041,647 shares of the company’s stock worth $60,551,000 after buying an additional 1,728,453 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Stock Performance

NASDAQ SVRA opened at $5.30 on Wednesday. Savara Inc. has a 1 year low of $1.98 and a 1 year high of $7.01. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.47 and a quick ratio of 13.47. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of -9.46 and a beta of 0.26. The company has a fifty day moving average price of $5.28 and a 200-day moving average price of $5.60.

Savara (NASDAQ:SVRA) last posted its earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). As a group, equities research analysts predict that Savara Inc. will post -0.57 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on SVRA. HC Wainwright restated a “buy” rating on shares of Savara in a report on Monday, March 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a report on Tuesday, April 21st. Oppenheimer began coverage on shares of Savara in a report on Friday, April 24th. They set an “outperform” rating and a $11.00 price objective on the stock. William Blair set a $10.00 price objective on shares of Savara in a report on Monday, March 16th. Finally, Wall Street Zen upgraded shares of Savara from a “sell” rating to a “hold” rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $10.14.

Savara Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.